JP2008532559A5 - - Google Patents

Download PDF

Info

Publication number
JP2008532559A5
JP2008532559A5 JP2008502456A JP2008502456A JP2008532559A5 JP 2008532559 A5 JP2008532559 A5 JP 2008532559A5 JP 2008502456 A JP2008502456 A JP 2008502456A JP 2008502456 A JP2008502456 A JP 2008502456A JP 2008532559 A5 JP2008532559 A5 JP 2008532559A5
Authority
JP
Japan
Prior art keywords
seq
immunoglobulin
immunoglobulin molecule
sequence
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008502456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008532559A (ja
Filing date
Publication date
Priority claimed from GB0505697A external-priority patent/GB0505697D0/en
Application filed filed Critical
Priority claimed from PCT/GB2006/000987 external-priority patent/WO2006100449A1/en
Publication of JP2008532559A publication Critical patent/JP2008532559A/ja
Publication of JP2008532559A5 publication Critical patent/JP2008532559A5/ja
Pending legal-status Critical Current

Links

JP2008502456A 2005-03-19 2006-03-20 ウイルス感染の治療及び予防又は治療及び予防の改善 Pending JP2008532559A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0505697A GB0505697D0 (en) 2005-03-19 2005-03-19 Improvements in or relating to treatment and prevention of viral infection
US31512305A 2005-12-23 2005-12-23
GB0526421A GB0526421D0 (en) 2005-03-19 2005-12-23 Improvements in or relating to treatment and prevention of viral infections
PCT/GB2006/000987 WO2006100449A1 (en) 2005-03-19 2006-03-20 Improvements in or relating to treatment and prevention of viral infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013121881A Division JP2013230152A (ja) 2005-03-19 2013-06-10 ウイルス感染の治療及び予防又は治療及び予防の改善

Publications (2)

Publication Number Publication Date
JP2008532559A JP2008532559A (ja) 2008-08-21
JP2008532559A5 true JP2008532559A5 (enExample) 2009-12-24

Family

ID=36754660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008502456A Pending JP2008532559A (ja) 2005-03-19 2006-03-20 ウイルス感染の治療及び予防又は治療及び予防の改善

Country Status (6)

Country Link
US (2) US20090110685A1 (enExample)
EP (2) EP2481424A1 (enExample)
JP (1) JP2008532559A (enExample)
AU (1) AU2006226192A1 (enExample)
CA (1) CA2601400A1 (enExample)
WO (1) WO2006100449A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101809033A (zh) * 2007-07-25 2010-08-18 日本国立感染症研究所 对丙型肝炎病毒(hcv)感染具有抑制活性的抗体和其用途
AU2008341542B2 (en) * 2007-12-17 2014-12-04 Medical Research Council Technology Hepatitis C virus antibodies
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
AU2009335788A1 (en) 2008-12-17 2011-07-07 Genentech, Inc. Hepatitis C virus combination therapy
CA2772613C (en) * 2009-09-03 2020-03-10 Schering Corporation Anti-gitr antibodies
CN102596996B (zh) * 2009-10-30 2014-06-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
ITFI20120122A1 (it) 2012-06-15 2013-12-16 Kedrion S P A 50 Anticorpi monoclonali capaci di legare la proteina virale e2 loro preparazione ed uso.
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
RU2539770C1 (ru) 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
CA2942540A1 (en) * 2014-03-20 2015-09-24 Takaji Wakita Antibody having infection-inhibiting activity against hepatitis c virus
EP3189077A2 (en) * 2014-09-05 2017-07-12 Aimm Therapeutics B.V. Hepatitis c virus specific antibody
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
SU1441787A1 (ru) 1987-04-29 1990-09-23 Институт Белка Ан Ссср Способ получени пептидов и белков в бесклеточной системе трансл ции
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
EP0446299A4 (en) 1988-11-18 1992-05-13 The Regents Of The University Of California Method for site-specifically incorporating unnatural amino acids into proteins
SU1705302A1 (ru) 1988-12-22 1992-01-15 Институт Белка Ан Ссср Способ препаративной экспрессии генов в бесклеточной системе сопр женной транскрипции/трансл ции
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP0593757B1 (en) 1989-07-31 1997-01-15 Institute Of Protein Research, Russian Academy Of Sciences Method for obtaining polypeptides in a cell-free system
CA2067194C (en) 1989-10-05 2003-03-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5654151A (en) 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU8498091A (en) 1990-08-02 1992-03-02 Regents Of The University Of Colorado, The Systematic polypeptide evolution by reverse translation
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
CA2098824A1 (en) 1990-12-20 1992-06-21 William D. Huse Optimization of binding proteins
IE920562A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
WO1996038579A1 (en) 1995-06-02 1996-12-05 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to growth factors
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
GB9603507D0 (en) * 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US5766686A (en) 1996-03-01 1998-06-16 North American Refractories Co. Spray insulating coating for refractory articles
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
US5887293A (en) 1998-01-28 1999-03-30 Hennessy; Arnold Simplified dump bucket toilet
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
WO2004041842A2 (en) * 2002-05-16 2004-05-21 The General Hospital Corporation Epitopes of hepatitis c virus
TWI358301B (en) * 2003-07-11 2012-02-21 Intercell Ag Hcv vaccines
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
AU2009335788A1 (en) * 2008-12-17 2011-07-07 Genentech, Inc. Hepatitis C virus combination therapy

Similar Documents

Publication Publication Date Title
US9145454B2 (en) Monoclonal antibodies for Ebola and Marburg viruses
JP2010518854A5 (enExample)
EP3082862B1 (en) Antibodies specific for enteroviruses that infect humans
RU2012112829A (ru) Анти-gitr-антитела
CN107921285A (zh) 多价乙型肝炎病毒抗原结合分子及其应用
JP2010502183A5 (enExample)
JP2005528914A5 (enExample)
JP2021159081A5 (enExample)
JP2008532559A5 (enExample)
RU2015151505A (ru) Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1)
JP2012518425A5 (enExample)
JP2007530551A5 (enExample)
RU2014118462A (ru) Gp41-нейтрализующие антитела и их применение
JP2011526249A5 (enExample)
JP2020505919A5 (enExample)
JPWO2020011964A5 (enExample)
JP2019507580A5 (enExample)
CN113583116A (zh) 针对SARS-CoV-1或SARS-CoV-2的抗体及其用途
JP2020515277A5 (enExample)
JP2019505166A5 (enExample)
JP2019504615A5 (enExample)
JPWO2020011966A5 (enExample)
JP2021512159A5 (enExample)
CN113527473A (zh) 一种全人源单克隆抗体及其应用
JPWO2020011976A5 (enExample)